Newsletter

Pipeline, markets, policy, and science. Once a week.

You’re in. Check your inbox to confirm.

More stories

Neoclassical federal agency building exterior at dawn, symbolizing a regulatory safety decision
Policy

Why the FDA Put a Vision-Loss Warning on Every GLP-1 Label

The agency combed trials, real-world claims data, and case reports for two years before putting NAION on every GLP-1 label. The absolute risk is tiny, the relative signal is real, and the decision says a lot about how FDA weighs incomplete evidence.

In depth

Merck and Moderna's Cancer Vaccine Beat Keytruda. The Harder Test Is Manufacturing.

Intismeran plus Keytruda cut melanoma recurrence or death risk by 42% versus Keytruda alone, a first Phase 3 win for a personalized mRNA vaccine. Moderna still fell as much as 25%.

Read the story

Pipeline

See all